Marc A. Cohen
Executive Chairman
Protein based therapeutics
C4 Therapeutics
United States of America
Biography
Marc A. Cohen is Co-founder and Executive Chairman of C4 Therapeutics. Marc is also the Co-founder and Chief Executive Officer of Bublup, Inc; Neuro Tennis, Inc.; and COBRO Ventures, Inc.; as well as the Co-founder and Chairman of Acetylon Pharmaceuticals, Inc. and OncoPep, Inc., two biotech companies spun out of Dana-Farber Cancer Institute and Harvard University. In addition, Marc was the Co-founder, Chief Executive Officer, and Chairman of OPNET Technologies, Inc (Nasdaq: OPNT), a world leader in network and application performance management. OPNET was sold to Riverbed Technology (Nasdaq: RVBD) in December 2012. Marc received a Bachelor of Science in engineering from Harvard University and a Master of Science in electrical engineering from Stanford University. Marc is a Trustee of the Dana-Farber Cancer Institute where he is focusing on accelerating translational research and increasing the flow of new therapies to patients. Marc enjoys tennis, yoga, and photography, and still hopes to figure out golf one day.
Research Interest
QUALITY OF PROTEINS WITHIN CELLS, USE OF DRUGS TO TARGET DISEASE-CAUSING PROTEINS FOR DESTRUCTION, TREATMENT OF CANCER AND OTHER DISEASES, AVOIDING TRADITIONAL DRUG RESISTANCE
